Noble Capital Markets Initiates Equity Research Coverage on The Oncology Institute, Inc. (TOI)
Noble Capital Markets (Noble), a full-service SEC / FINRA-registered broker-dealer dedicated exclusively to serving public and private middle market companies and their investors, has initiated equity research coverage on The Oncology Institute, Inc.
Noble’s Equity Research Analyst Robert LeBoyer launched coverage today with his report titled “Improving Oncology Treatment While Cutting Costs”. The full report can be viewed, at no cost, on Channelchek.com.
The Oncology Institute, Inc. (Nasdaq: TOI) offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financia, counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services.
About Noble Capital Markets
Established in 1984, Noble Capital Markets is an SEC / FINRA registered full-service investment bank and advisory firm with an award-winning research team and proprietary investor distribution platform. We deliver middle market expertise to entrepreneurs, corporations, financial sponsors, and investors. Over the past 40 years, Noble has raised billions of dollars for companies and published more than 45,000 equity research reports.
About Channelchek
Noble launched www.channelchek.com in 2018 – an investor community dedicated exclusively to public emerging growth companies and their industries. Channelchek is the first service to offer institutional-quality research to the public, for FREE at every level without a subscription. More than 7,000 public emerging growth companies are listed on the site, and content including equity research, webcasts, and industry articles.